Acute Parkinsonism

  • Hubert H. FernandezEmail author
  • Joseph H. Friedman
Part of the Current Clinical Neurology book series (CCNEU)


Acute onset parkinsonism is rare. The most common explanations are neuroleptic malignant syndrome, viral encephalitis, psychogenic, and catatonia. Testing, including cerebrospinal fluid analyses, toxicology, routine blood evaluations, imaging, and electroencephalograpy, assumes a much greater role than the evaluation of degenerative forms of parkinsonism. Acute parkinsonism should always be considered an emergency. Catatonia and neuroleptic malignant syndrome are treatable disorders that are often readily reversed. Viral encephalitis usually requires aggressive supportive care. Other, less common forms are also discussed in this chapter.


Dopamine Agonist Influenza Pandemic Neuroleptic Malignant Syndrome Progressive Multifocal Leukoencephalopathy Lenticular Nucleus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material (54,258) KB


  1. 1.
    Friedman JH. Drug induced parkinsonism. In: Lang AE, Weiner WJ, editors. Drug-induced movement disorders. Mt Kisco: Futura Press; 1992. p. 41–84.Google Scholar
  2. 2.
    Fahn S, Przedborski S. Parkinsonism. In: Rowland LP, editor. Merritt’s textbook of neurology. 11th ed. Philadelphia: Lippincott Williams and Williams; 2005. p. 828–46.Google Scholar
  3. 3.
    Caligiuri MP, Ellwanger J. Motor and cognitive aspects of motor retardation in depression. J Affect Disord. 2000;47:83–93.CrossRefGoogle Scholar
  4. 4.
    Hymas N, Lees A, Bolton D, et al. The neurology of obsessional slowness. Brain. 1991;114:2203–33.PubMedCrossRefGoogle Scholar
  5. 5.
    Curran T, Lang AE. Parkinsonian syndromes associated with hydrocephalus: case reports, a review of the literature and pathophysiological hypotheses. Mov Disord. 1994;9:508–20.PubMedCrossRefGoogle Scholar
  6. 6.
    Sakurai T, Kimura A, Yamada M, et al. Rapidly progressive parkinsonism that developed one year after ventriculoperitoneal shunting for idiopathic aqueductal stenosis: a case report. Brain Nerve. 2010;62:527–31.PubMedGoogle Scholar
  7. 7.
    Lees AJ. Secondary Parkinson’s syndrome. In: Jankovic JJ, Tolosa E, editors. Parkinson’s disease and movement disorders. 5th ed. Philadelphia: Lippincott Williams and Williams; 2007. p. 213–24.Google Scholar
  8. 8.
    Boecker H, Weindl A, Leenders K, et al. Secondary parkinsonism due to focal substantia nigra lesions: a PET study with (18F)FDG and (18F)fluorodopa. Acta Neurol Scand. 1996;93:387–92.PubMedCrossRefGoogle Scholar
  9. 9.
    Stern G. The effects of lesions in the substantia nigra. Brain. 1966;89:449–78.PubMedCrossRefGoogle Scholar
  10. 10.
    Hunter R, Smith J, Thomson T, Dayan AD. Hemiparkinsonism with infarction of the ilpsilateral substantia nigra. Neuropathol Appl Neurobiol. 1978;4:297–301.PubMedCrossRefGoogle Scholar
  11. 11.
    Kim JS. Involuntary movements after anterior cerebral artery territory infarction. Stroke. 2001;32:258–61.PubMedCrossRefGoogle Scholar
  12. 12.
    Nagaratnam N, Davies D, Chen E. Clinical effects of anterior cerebral artery infarction. J Stroke Cerebrovasc Dis. 1998;7:391–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Dick JP, Benecke R, Rothwell JC, et al. Simple and complex movements in a patient with infarction of the right supplementary motor area. Mov Disord. 1986;1:255–66.PubMedCrossRefGoogle Scholar
  14. 14.
    Russmann H, Vingerhoets F, Ghika J, et al. Acute infarction limited to the lenticular nucleus: clinical, etiologic and topographic features. Arch Neurol. 2003;60:351–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Turjanski N, Pentland B, Lees AJ, Brooks DJ. Parkinsonism associated with acute intracranial hematomas: an (18F)Dopa positron-emission tomography study. Mov Disord. 1997;12: 1035–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Orta Daniel SJ, Ulises RO. Stroke of the substantia nigra and parkinsonism as the first manifestation of systemic lupus erythematosis. Parkinsonism Relat Disord. 2008;14:367–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Wang JD, Huang CC, Hwang YH, et al. Manganese induced parkinsonism: an outbreak due to an unrepaired ventilation control system in a ferromanganese smelter. Br J Ind Med. 1989;46:856–9.PubMedGoogle Scholar
  18. 18.
    Feldman RG. Manganese. In: Occupational and environmental medicine. Philadelphia: Lippincott Raven Press; 1999. p. 168–188.Google Scholar
  19. 19.
    Sohn YH, Jeong Y, Kim HS, Im JH, Kim JS. The brain lesion responsible for parkinsonism after carbon monoxide poisoning. Arch Neurol. 2000;57:1214–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Perry GF. Occupational medicine forum. What are the potential delayed health effects of high level carbon monoxide exposure? J Occup Med. 1994;36:595–7.Google Scholar
  21. 21.
    Shprecher D, Mehta L. The syndrome of delayed post-hypoxic leukoencephalopathy. NeuroRehabilitation. 2010;26:65–72.PubMedGoogle Scholar
  22. 22.
    Okuda B, Iwamoto Y, Tachibana H, Sugita M. Parkinsonism after acute cadmium poisoning. Clin Neurol Neurosurg. 1997;99:263–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Barbosa ER, Comerlatti LR, Haddad MS, Scaff M. Parkinsonism secondary to ethylene oxide exposure: case report. Arq Neurosiquiatr. 1992;50:531–3.CrossRefGoogle Scholar
  24. 24.
    Laplane D, Attal N, Sauron B, et al. Lesions of the basal ganglia due to disulfiram neurotoxicity. J Neurol Neurosurg Psychiatry. 1992;44:925–9.CrossRefGoogle Scholar
  25. 25.
    Messing B. Extrapyramidal disturbance after cyanide poisoning. J Neural Transm Suppl. 1991;33:141–7.PubMedGoogle Scholar
  26. 26.
    Pentore R, Venneri A, Nichelli P. Accidental choke-cherry poisoning: early symptoms and neurological sequelae of an unusual case of cyanide intoxication. Ital J Neurol Sci. 1996;17:233–5.PubMedCrossRefGoogle Scholar
  27. 27.
    Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine analogue synthesis. Science. 1983;219:979–80.PubMedCrossRefGoogle Scholar
  28. 28.
    Leopold NA, Bara-Jimenez W, Hallett M. Parkinsonism after a wasp sting. Mov Disord. 1999;14:122–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Agarwal V, Singh R, Chauhau S, J’Cruz S, Thakur R. Parkinsonism following a honey bee sting. Indian J Med Sci. 2006;60:24–5.PubMedCrossRefGoogle Scholar
  30. 30.
    Bogolepov NK, Luzhetskaya TA, Fedin AI, et al. Allergic encephalomyelopolyradiculoneuritis from a wasp sting (clinico-patholo report). Zh Nevropatol Psikhiatr Im SS Korsakova. 1978;78:187–91.Google Scholar
  31. 31.
    Shandling M, Carlen PL, Lang AE. Parkinsonism in alcohol withdrawal: a follow-up study. Mov Disord. 1990;4:36–9.CrossRefGoogle Scholar
  32. 32.
    Carlen PL, Lee MA, Jacob M, Livishitz O. Parkinsonism provoked by alcoholism. Ann Neurol. 1981;9:84–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Lang AE, Marsden CD, Obeso JA, Parkes JD. Alcohol and Parkinson disease. Ann Neurol. 1982;12:254–6.PubMedCrossRefGoogle Scholar
  34. 34.
    San Luciano M, Saunders-Pullman R. Substance abuse and movement disorders. Curr Drug Abuse Rev. 2009;2:273–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Tinker R, Anderson MG, Anand P, et al. Pontine myelinolysis presenting with acute parkinsonism as a sequel of corrected hyponatremia. J Neurol Neurosurg Psychiatry. 1990;53:87–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Dickoff DJ, Rapps M, Yahr MD. Striatal syndrome following hyponatremia and its rapid correction. Arch Neurol. 1988;45:112–4.PubMedCrossRefGoogle Scholar
  37. 37.
    Bernardini GL, Mancall EL. Central pontine myelinolysis. In: Rowland LP, editor. Merritt’s neurology. 11th ed. Philadelphia: Lippincott Williams and Wilins; 2005. p. 965–7.Google Scholar
  38. 38.
    Hawker K, Lang AE. Hypoxic-ischemic damage of the basal ganglia: case reports and a review of the literature. Mov Disord. 1990;5:219–24.PubMedCrossRefGoogle Scholar
  39. 39.
    Straussberg R, Shahar E, Gat R, Brand N. Delayed parkinsonism associated with hypotension in a child undergoing open-heart surgery. Dev Med Child Neurol. 1993;35:1007–14.Google Scholar
  40. 40.
    Li JY, Lai PH, Chen CY, et al. Postanoxic parkinsonism: clinical radiologic and pathologic correlation. Neurology. 2000;55:591–3.PubMedCrossRefGoogle Scholar
  41. 41.
    Gillman PK. Neuroleptic malignant syndrome: mechanisms, interactions and causality. Mov Disord. 2010;25:1780–90.PubMedCrossRefGoogle Scholar
  42. 42.
    Carbone JR. The neuroleptic malignant syndrome and serotonin syndromes. Emerg Clin North Am. 2000;18:317–25.CrossRefGoogle Scholar
  43. 43.
    Susman VL. Clinical management of neuroleptic malignant syndrome. Psychiatr Q. 2001;72:325–6.PubMedCrossRefGoogle Scholar
  44. 44.
    Perrin E, Anand E, Dyachkova Y, et al. A prospective observational study of the safety and effectiveness of intramuscular psychotropic treatment in acutely agitated patients with schizophrenia and bipolar mania. Eur Psychiatry. 2012;27(4):234–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Lockman LA, Sung JH, Krivit W. Acute parkinsonian syndrome with demyelinating leukoencephalopathy in bone marrrow transplant recipients. Pediatr Neurol. 1991;7:457–63.PubMedCrossRefGoogle Scholar
  46. 46.
    Devinsky O, Lemann W, Evans AC, et al. Akinetic mutism in a bone marrow transplant recipient following total-body irradiation and amphotericin B chemoprophylaxis: a positron emission tomographic and neuropathologic study. Arch Neurol. 1987;44:414–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Chuang C, Constantino A, Balmaceda C, et al. Chemotherapy-induced parkinsonism responsive to levodopa: an under-recognized entity? Mov Disord. 2003;18:328–31.PubMedCrossRefGoogle Scholar
  48. 48.
    Lima MA, Maradei S, Maranhao Filho P. Cyclosporin-induced parkinsonism. J Neurol. 2009;245:674–5.CrossRefGoogle Scholar
  49. 49.
    Shahar E, Goshen E, Tauber Z, Lahat E. Parkinsonian syndrome complicating systemic lupus erythematosus. Pediatr Neurol. 1998;18:456–8.PubMedCrossRefGoogle Scholar
  50. 50.
    Yancey CL, Doughty RA, Athreya BH. Central nervous system involvement in childhood system lupus erythematosis. Arthritis Rheum. 1981;24:1389–95.PubMedCrossRefGoogle Scholar
  51. 51.
    Francis A. Catatonia: diagnosis, classification and treatments. Curr Psychiatry Rep. 2010;12:180–5.PubMedCrossRefGoogle Scholar
  52. 52.
    Friedman JH. Stereotypy and catatonia. In: Jankovic JJ, Tolosa E, editors. Parkinson’s disease and movement disorders. 5th ed. Baltimore, MD, USA: Williams and Wilkins; 2007. p. 468–80.Google Scholar
  53. 53.
    Bush G, Fink M, Petrides G, et al. Catatonia: 2. Treatment with lorazepam and electroconvulsive therapy. Acta Psychiatr Scand. 1996;93:137–43.PubMedCrossRefGoogle Scholar
  54. 54.
    Factor SA, Podskalny GD, Molho ES. Psychogenic movement disorders: frequency, clinical profile and characteristics. J Neurol Neurosurg Psychiatry. 1994;59:406–12.CrossRefGoogle Scholar
  55. 55.
    Trimble MR. Clinical presentations in neuropsychiatry. Semin Clin Neuropsychiatry. 2002;7:11–7.PubMedCrossRefGoogle Scholar
  56. 56.
    Lang AE, Koller WC, Fahn S. Psychogenic parkinsonism. Arch Neurol. 1995;52:802–10.PubMedCrossRefGoogle Scholar
  57. 57.
    Koller WC, Findley LI. Psychogenic tremors. Adv Neurol. 1990;53:271–5.PubMedGoogle Scholar
  58. 58.
    Von Economo C. Encephalitis lethargica. Wien Klin Wochenschr. 1917;30:581–5.Google Scholar
  59. 59.
    Urechia CL. Dix cas d’encephalite epidemique avec autopsie. Arch Inter Neurol. 1921;2:65–78.Google Scholar
  60. 60.
    Cruchet R, Moutier F, Calmette A. Quarante cas d’encephalo-myelite subaigue. Bull Mem Soc Med d’Hop. 1917;41:614–6.Google Scholar
  61. 61.
    Etienne G. Myelities aigues epidemiques. Deux épidémies militares. Rev Neurol. 1917;24:375–6.Google Scholar
  62. 62.
    Watson AJ. Origin of encephalitis lethargica. Chin Med J. 1928;42:427–32.Google Scholar
  63. 63.
    Von Economo C. Encephalitis lethargica: its sequelae and treatment (translated by K.O. Newman). London: Oxford University Press; 1931. p. I–XIV. 1–200.Google Scholar
  64. 64.
    Duvoisin RC, Yahr MD. Encephalitis and parkinsonism. Arch Neurol. 1965;12:227–39.PubMedCrossRefGoogle Scholar
  65. 65.
    Geddes JF, Hughes AJ, Lees AJ, Daniel SE. Pathological overlap in cases of parkinsonism associated with neurofibrillary tangles. Brain. 1993;116:281–2.PubMedCrossRefGoogle Scholar
  66. 66.
    Wilson SAK. Epidemic encephalitis. In: Neurology. Volume 1. Baltimore: Williams and Wilkins C; 1940. p. 118–65.Google Scholar
  67. 67.
    Morrison PJ, Patterson VH. Cranial dystonia (Meige syndrome) in postencephalitic parkinsonism. Mov Disord. 1992;7:90–1.PubMedCrossRefGoogle Scholar
  68. 68.
    Wenning GK, Jellinger K, Litvan I. Supranuclear gaze palsy and eyelid apraxia in postencephalitic parkinsonism. J Neural Transm. 1997;104:845–65.PubMedCrossRefGoogle Scholar
  69. 69.
    Litvan I, Jankovic J, Goetz CG. Accuracy of the clinical diagnosis of postencephalitic parkinsonism: a clinicopathologic study. Eur J Neurol. 1998;5:451–7.PubMedCrossRefGoogle Scholar
  70. 70.
    Vilensky JA, Gilman S, McCall S. A historical analysis of the relationship between encephalitis lethargica and post-encephalitic parkinsonism: a complex rather than a direct relationship. Mov Disord. 2010;25:116–23.Google Scholar
  71. 71.
    Duncan AG. The sequelae of encephalitis lethargica. Brain. 1924;47:76–108.CrossRefGoogle Scholar
  72. 72.
    Calne DB, Lees AJ. Late progression of post-encephalitic Parkinson syndrome. Can J Neurol Sci. 1988;15:135–8.PubMedGoogle Scholar
  73. 73.
    Vieregge P, Reinhardt V, Hoft B. Is progression in postencephalitic Parkinson’s disease late and age-related? J Neurol. 1991;238:299–303.PubMedGoogle Scholar
  74. 74.
    Ravenholt RT, Foege WH. 1918 Influenza, encephalitis lethargica, parkinsonism. Lancet. 1982;2:860–2.PubMedCrossRefGoogle Scholar
  75. 75.
    Laidlaw PP. Epidemic influenza: a virus disease. Lancet. 1935;1:1118–24.CrossRefGoogle Scholar
  76. 76.
    Casals J, Elizan TS, Yahr MD. Postencephalitic parkinsonism—a review. J Neural Transm. 1998;105:645–76.PubMedCrossRefGoogle Scholar
  77. 77.
    Gamboa ET, Wolf A, Yahr MD, et al. Influenza virus antigen in postencephalitic parkinsonism brain. Arch Neurol. 1974;31:228–32.PubMedCrossRefGoogle Scholar
  78. 78.
    Martilla RJ, Halomen P, Rinne UK. Influenza virus antibodies in parkinsonism. Comparison of postencephalitic and idiopathic Parkinson patients and matched controls. Arch Neurol. 1977;34:99–100.CrossRefGoogle Scholar
  79. 79.
    Elizan T, Schwartz J, Yahr MD, Casals J. Antibodies against arboviruses in postencephalitic and idiopathic Parkinson’s disease. Arch Neurol. 1978;35:257–60.PubMedCrossRefGoogle Scholar
  80. 80.
    Takahashi M, Yamada T, Nakajima S, et al. The substantia nigra is a major target for neurovirulent influenza A virus. J Exp Med. 1995;181:2161–9.PubMedCrossRefGoogle Scholar
  81. 81.
    Elizan TS, Casals J, Yahr MD. Antineurofilament antibodies in postencephalitic and idiopathic Parkinson’s disease. J Neurol Sci. 1983;59:341–7.PubMedCrossRefGoogle Scholar
  82. 82.
    Elizan TS, Yahr MD. Histocompatibility antigens and postencephalitic parkinsonism. J Neurol Neurosurg Psychiatry. 1983;46:688–93.PubMedCrossRefGoogle Scholar
  83. 83.
    Lees AJ, Stern GM, Compston DAS. Histocompatibility antigens and post-encephalitic parkinsonism. J Neurol Neurosurg Psychiatry. 1982;45:1060–1.PubMedCrossRefGoogle Scholar
  84. 84.
    Williams A, Houff S, Lees A, Calne DB. Oligoclonal banding in the cerebrospinal fluid of patients with postencephalitic parkinsonism. J Neurol Neurosurg Psychiatry. 1979;42:790–2.PubMedCrossRefGoogle Scholar
  85. 85.
    Rail D, Scholtz C, Swash M. Postencephalitic parkinsonism: current experience. J Neurol Neurosurg Psychiatry. 1981;44:670–6.PubMedCrossRefGoogle Scholar
  86. 86.
    Clough CG, Plaitakis A, Yahr MD. Oculogyric crises and parkinsonism: a case of recent onset. Arch Neurol. 1983;40:36–7.PubMedCrossRefGoogle Scholar
  87. 87.
    Johnson J, Lucey PA. Encephalitis lethargica, a contemporary cause of catatonic stupor: a report of two cases. Br J Psychiatry. 1987;151:550–2.PubMedCrossRefGoogle Scholar
  88. 88.
    Howard RS, Lees AJ. Encephalitis lethargica. A report of four recent cases. Brain. 1987;110:19–33.PubMedCrossRefGoogle Scholar
  89. 89.
    Misra UK, Kalita J. Spectrum of movement disorders in encephalitis. J Neurol. 2010;257: 2052–8.PubMedCrossRefGoogle Scholar
  90. 90.
    Ghaemi M, Rudolf S, Schmulling S, Bamborschke S, Heiss WD. FDG- and Dopa-PET in postencephalitic parkinsonism. J Neural Transm. 2000;107:1289–95.PubMedCrossRefGoogle Scholar
  91. 91.
    Cree BC, Bernardini GL, Hays AP, Lowe G. A fatal case of coxackievirus B4 meningoencephalitis. Arch Neurol. 2003;60:107–8.PubMedCrossRefGoogle Scholar
  92. 92.
    Nath A, Jankovic J, Pettigrew LC. Movement disorders and AIDS. Neurology. 1987;37:37–41.PubMedCrossRefGoogle Scholar
  93. 93.
    Carranzana EJ, Rossitch E, Samuels MA. Parkinsonian symptoms in a patient with AIDS and cerebral toxoplasmosis. J Neurol Neurosurg Psychiatry. 1989;12:1445–7.CrossRefGoogle Scholar
  94. 94.
    Navia BA, Petito CK, Gold JWM, et al. Cerebral toxoplasmosis complicating the acquired immunodeficiency syndrome: clinical and neuropathological findings in 27 patients. Ann Neurol. 1986;19:224–38.PubMedCrossRefGoogle Scholar
  95. 95.
    Noel S, Gaillaume MP, Telerman-Toppet N, et al. Movement disorders due to cerebral Toxoplasma gondii infection in patients with the acquired immunodeficiency syndrome (AIDS). Acta Neurol Belg. 1992;92:148–56.PubMedGoogle Scholar
  96. 96.
    Maggi P, de Mari M, Moramarco A, Fiorentino P, Lamberti P, Angarano G. Parkinsonism in a patient with AIDS and cerebral opportunistic granulomatous lesions. Neurol Sci. 2002;21:173–6.CrossRefGoogle Scholar
  97. 97.
    De Mattos JP, Rosso AL, Correa RD, et al. Involuntary movements and AIDS: report of seven cases and review of the literature. Arq Neuropsiquiatr. 1993;51:491–7.PubMedCrossRefGoogle Scholar
  98. 98.
    Misattari SM, Power C, Nath A. Parkinsonism with HIV infection. Mov Disord. 1998;13:684–9.CrossRefGoogle Scholar
  99. 99.
    Cardoso F. HIV-related movement disorders: epidemiology, pathogenesis and management. CNS Drugs. 2002;16:663–8.PubMedCrossRefGoogle Scholar
  100. 100.
    Sandyk R. Parkinsonism secondary to neurosyphilis: a case report. S Afr Med J. 1983;23:665–6.Google Scholar
  101. 101.
    Garcia-Moreno JM, Izquierdo G, Chacon J, Angulo S, Borobio MV. Neuroborreliosis in a patient with progressive supranuclear paralysis: an association or a cause? Rev Neurol. 1997;25:1919–21.PubMedGoogle Scholar
  102. 102.
    Zambrino CA, Zorzi G, Lanzi G, Uggetti C, Egitto MC. Bilateral striatal necrosis associated with mycoplasma pnuemoniae infection in an adolescent: clinical and neurodiagnostic follow-up. Mov Disord. 2000;15:1023–6.PubMedCrossRefGoogle Scholar
  103. 103.
    Al-Mateen M, Gibbs M, Dietrch R, Mitchell WG, Menkes JH. Encephalitis lethargica-like illness in a girl with mycoplasma infection. Neurology. 1988;38:1155–8.PubMedCrossRefGoogle Scholar
  104. 104.
    Saitoh S, Wada T, Narita M, et al. Mycoplasma pneumoniae infection may cause striatal lesions leading to acute neurological dysfunction. Neurology. 1993;43:2150–1.PubMedCrossRefGoogle Scholar
  105. 105.
    Kim JS, Choi IS, Lee MC. Reversible parkinsonism and dystonia following probable mycoplasma pneumoniae infection. Mov Disord. 1995;10:510–2.PubMedCrossRefGoogle Scholar
  106. 106.
    Brandel J, Noseda G, Agid Y. Mycoplasma pneumoniae postinfectious encephalomyelitis with bilateral striatal necrosis. Mov Disord. 1996;11:333–5.PubMedCrossRefGoogle Scholar
  107. 107.
    Singer C, Berger JR, Bowen BC, Bruce JH, Weiner WJ. Akinetic-rigid syndrome in a 13-year old girl with HIV-related progressive multifocal leukoencephalopathy. Mov Disord. 1993;8:113–6.PubMedCrossRefGoogle Scholar
  108. 108.
    Werring DJ, Chaudhuri KR. HIV-related progressive multifocal leukoencephalopathy presenting with an akinetic-rigid syndrome. Mov Disord. 1996;11:758–61.PubMedCrossRefGoogle Scholar
  109. 109.
    De la Fuente J, Bordon J, Moreno JA, et al. Parkinsonism in an HIV-infected patient with hypodense cerebral lesion. Tuber Lung Dis. 1996;77:191–2.CrossRefGoogle Scholar
  110. 110.
    Strong G. Parkinson’s syndrome following herpes ophthalmicus. Br Med J. 1952;1:533.PubMedCrossRefGoogle Scholar
  111. 111.
    Fenichel GM. Postvaccinal parkinsonism. Mov Disord. 1993;8:253.PubMedGoogle Scholar
  112. 112.
    Reijneveld JC, Taphoorn MJB, Hoogenraad TU, Van Gijn J. Severe but transient parkinsonism after tetanus vaccination. J Neurol Neurosurg Psychiatry. 1997;63:258–9.PubMedCrossRefGoogle Scholar
  113. 113.
    McCall S, Henry JM, Reid AH, Taubenberger JK. Influenza RNA not detected in archival brain tissues from acute encephalitis lethargica cases or in postencephalitic parkinson cases. J Neuropathol Exp Neurol. 2001;60:696–704.PubMedGoogle Scholar
  114. 114.
    Krusz JC, Koller WC, Ziegler DK. Historical review: abnormal movements associated with epidemic encephalitis lethargica. Mov Disord. 1987;2:137–41.PubMedCrossRefGoogle Scholar
  115. 115.
    Elizan TS, Casals J. Astrogliosis in von Economo’s and postencephalitic Parkinson’s diseases supports probable viral etiology. J Neurol Sci. 1991;105:131–4.PubMedCrossRefGoogle Scholar
  116. 116.
    Hof PR, Charpiot A, Delacourte A, et al. Distribution of neurofibrillary tangles and senile plaques in the cerebral cortex in postencephalitic parkinsonism. Neurosci Lett. 1992;139:10–4.PubMedCrossRefGoogle Scholar
  117. 117.
    Josephs KA, Parisi JE, Dickson DW. Alpha-synuclein studies are negative in postencephalitic parkinsonism of von Economo. Neurology. 2002;59:645–6.PubMedCrossRefGoogle Scholar
  118. 118.
    Ikeda K, Akiyama H, Kondo H, Ikeda K. Anti-tau-positive glial fibrillary tangles in the brain of post-encephalitic parkinsonism of Economo type. Neurosci Lett. 1993;162(1–2):176–8.Google Scholar
  119. 119.
    Wong KT, Allen IV, McQuaid S, McConnell R. An immunohistochemical study of neurofibrillary tangle formation in post-encephalitic parkinsonism. Clin Neuropathol. 1996;15:22–5.PubMedGoogle Scholar
  120. 120.
    Shen WC, Ho YJ, Lee SK, Lee KR. MRI of transient post-encephalitic parkinsonism. J Comput Assist Tomogr. 1994;18:155–9.PubMedCrossRefGoogle Scholar
  121. 121.
    Caparros-Lefebvre D, Cabaret M, Godefroy O, et al. PET study and neuropsychological assessment of a long-lasting post-encephalitic parkinsonism. J Neural Transm. 1998;105:489–95.PubMedCrossRefGoogle Scholar
  122. 122.
    Solbrig MV, Nashef L. Acute parkinsonism in suspected herpes simplex encephalitis. Mov Disord. 1993;8:233–4.PubMedCrossRefGoogle Scholar
  123. 123.
    Savant CS, Singhal BS, Jankovic J, Khan MAK, Virani A. Substantia nigra lesions in viral encephalitis. Mov Disord. 2003;18:213–27.PubMedCrossRefGoogle Scholar
  124. 124.
    Alves RSC, Barbosa ER, Scaff M. Postvaccinal parkinsonism. Mov Disord. 1992;7:178–80.PubMedCrossRefGoogle Scholar
  125. 125.
    Calne DB, Stern GM, Laurence DR. L-dopa in postencephalitic parkinsonism. Lancet. 1969;1:744–6.PubMedCrossRefGoogle Scholar
  126. 126.
    Sacks O. Awakenings. New York: Harper Perennial; 1990.Google Scholar
  127. 127.
    Duvoisin RC, Lobo-Antunes J, Yahr MD. Response of patients with post-encephalitic parkinsonism to levodopa. J Neurol Neurosurg Psychiatry. 1972;35:487–95.PubMedCrossRefGoogle Scholar
  128. 128.
    Walters JH. Postencephalitic parkinson syndrome after meningoencephalitis due to coxackie virus group B, type 2. N Engl J Med. 1960;263:744–7.CrossRefGoogle Scholar
  129. 129.
    Posner CM, Huntley CJ, Poland JD. Para-encephalitic parkinsonism. Acta Neurol Scand. 1969;45:199–215.CrossRefGoogle Scholar
  130. 130.
    Giraldi C, Mazzoni M, Morgantini PG, Lunardi CV. Parkinsonian syndrome during viral encephalitis. Riv Neurol. 1991;61:183–5.PubMedGoogle Scholar
  131. 131.
    Ickenstein GW, Klotz JM, Langorh HD. Virus encephalitis with symptomatic parkinsonian syndrome, diabetes insipidus and panhypopituitarism. Fortschr Neurol Psychiatr. 1999;67: 476–81.PubMedCrossRefGoogle Scholar
  132. 132.
    Hsieh JC, Lue KH, Lee YL. Parkinson-like syndrome as the major presenting symptom of Epstein-Barr virus encephalitis. Arch Dis Child. 2002;87:358–9.PubMedCrossRefGoogle Scholar
  133. 133.
    Isgreen WP, Chutarian AM, Fahn S. Sequential parkinsonism and chorea following “mild” influenza. Trans Am Neurol Assoc. 1976;101:56–9.PubMedGoogle Scholar
  134. 134.
    Shiraki H, Goto A, Narabayashi H. Etat passe et present de l’encephalite Japonnaise au Japon. Rev Neurol (Paris). 1963;108:633–96.Google Scholar
  135. 135.
    Ishii T, Marsushita M, Hamada S. Characteristic residual neuropathological features of Japanese B encephalitis. Acta Neuropathol (Berl). 1977;38:181–6.CrossRefGoogle Scholar
  136. 136.
    Shoji H, Watanabe M, Itoh S, Kuwahara H, Hattori F. Japanese encephalitis and parkinsonism. J Neurol. 1993;240:59–60.PubMedCrossRefGoogle Scholar
  137. 137.
    Pradham S, Pandey N, Shashank S, et al. Parkinsonism due to predominant involvement of the substantia nigra in Japanese encephalitis. Neurology. 1999;53:1781–6.CrossRefGoogle Scholar
  138. 138.
    Scheid W, Ackerman R, Felgenhauer K. Lymphozytare choriomeningitis unter dem bild der Encephalitis lethargica. Dtsch Med Wochenschr. 1968;93:940–3.PubMedCrossRefGoogle Scholar
  139. 139.
    Adair CV, Gould RL, Smadel JE. Aseptic meningitis, a disease of diverse etiology: clinical and etiological studies of 854 cases. Ann Intern Med. 1953;39:675–704.PubMedGoogle Scholar
  140. 140.
    Bennett NMcK. Murray Valley encephalitis, 1947: clinical features. Med J Aust. 1976;2:446–50.PubMedGoogle Scholar
  141. 141.
    Bickerstaff ER, Cloake PCP. Mesencephalitis and rhombencephalitis. Br Med J. 1951;2:77–81.PubMedCrossRefGoogle Scholar
  142. 142.
    Thieffrey S. Enterovirus et maladies du systeme nerveux: revisiou critique et experience personnelle. Rev Neurol (Paris). 1963;108:753–76.Google Scholar
  143. 143.
    Barrett AM, Gairdner D, McFarlan AM. An outbreak of encephalitis possibly due to poliomyitis virus. Br Med J. 1952;1:1317–22.PubMedCrossRefGoogle Scholar
  144. 144.
    Vincent FM, Myers WG. Poliomyelitis and parkinsonism. N Engl J Med. 1978;298:688–9.PubMedCrossRefGoogle Scholar
  145. 145.
    Mellon AF, Appleton RE, Gardner-Medwin D, Aynsley-Green A. Encephalitis lethargica-like illness in a 5 year old. Dev Med Child Neurol. 1991;33:153–6.Google Scholar
  146. 146.
    Meyer B. Encephalitis after measles with severe parkinsonian rigidity: recovery. Br Med J. 1943;1:508.PubMedCrossRefGoogle Scholar
  147. 147.
    Henner K, Hanzal F. Encephalite tchecoslavaque a tiques. Rev Neurol (Paris). 1957;96:384–408.Google Scholar
  148. 148.
    Henner K, Hanzal F. Les encephalities europeenes a tiques. Rev Neurol (Paris). 1963;108:697–752.Google Scholar
  149. 149.
    Radsel-Melvescek A, Marolt-Gomiscek M, Pouse-Trojar M, Gajsek-Zima M. Late sequelae after tick-borne meningoencephalitis in patients treated at the hospital for infectious diseases at University Medical Centre of Ljubljana during the period 1974–1975. Zentralbl Bakteriol. 1980;9(suppl):281–4.Google Scholar
  150. 150.
    Cerna F, Mehrad B, JP Luby, et al. St. Louis encephalitis and the substantia nigra: MR imaging evaluation. Am J Neuroradiol. 1999;20:1281–3.PubMedGoogle Scholar
  151. 151.
    Wasay M, Diaz-Arastia R, Suss R, et al. St. Louis encephalitis: a review of 11 cases in a 1995 Dallas, Texas epidemic. Arch Neurol. 2000;57:114–8.PubMedCrossRefGoogle Scholar
  152. 152.
    Finley KH. Postencephalitic manifestations of viral encephalitides. In: Fields WS, Blattner RJ, editors. Viral encephalitis. Springfield Ill: CC Thomas; 1958. p. 69–94.Google Scholar
  153. 153.
    Finley KH, Riggs N. Convalescence and sequelae. In: Monath TP, editor. St. Louis encephalitis. Washington DC: Am Pub Hlth Assoc; 1980. p. 535–50.Google Scholar
  154. 154.
    Fulton JC, Burton AN. After effects of WEE infection in man. Canad MAJ. 1953;69: 268–72.Google Scholar
  155. 155.
    Mulder DW, Parrot M, Thaler M. Sequelae of western equine encephalitis. Neurology. 1951;1:318–27.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Center for Neurological Restoration, Cleveland ClinicClevelandUSA
  2. 2.Movements Disorders ProgramButler HospitalProvidenceUSA
  3. 3.Movement Disorders Division, Department of NeurologyAlpert Medical School of Brown University, Butler HospitalProvidenceUSA

Personalised recommendations